周三，花旗开始对吉利德科学公司(NASDAQ:GILD)进行覆盖，给予该股买入评级，并将目标价设定为125美元。这一积极展望基于多个因素，包括公司HIV治疗药物Biktarvy的预期增长，以及即将推出的药物lenacapavir的潜力。

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...